Purpose of This Guideline
Date of current publication: September 12, 2023
Lead author: Tiffany Lu, MD, MS
Writing group: Susan D. Whitley, MD; Timothy J. Wiegand, MD; Sharon L. Stancliff, MD; Christopher J. Hoffmann, MD, MPH; Charles J. Gonzalez, MD
Committee: Substance Use Guidelines Committee
Date of original publication: August 29, 2019
This guideline was developed by the New York State Department of Health AIDS Institute (NYSDOH AI) to inform clinicians who do not specialize in substance use treatment of the currently available and effective strategies for treating adult patients with opioid use disorder (OUD). With this guideline, the NYSDOH AI aims to:
- Assist clinicians in engaging with patients about OUD treatment goals, including overdose prevention.
- Provide up-to-date information about available OUD treatment options and their use.
- Provide clinical recommendations for the use of buprenorphine/naloxone to treat OUD in the nonspecialty setting.
- Increase the availability of nonspecialty treatment for adults with OUD.
- Promote a harm reduction approach to the treatment of all substance use disorders (SUDs), which involves practical strategies and ideas for reducing the negative consequences associated with substance use.
Goals of OUD Treatment
The United States is in the midst of an unprecedented opioid crisis, with dramatic increases observed in opioid use, OUD, and opioid-related overdose deaths SAMHSA(a) 2021; Scholl, et al. 2018; Rudd, et al. 2016. Data from the Centers for Disease Control and Prevention show an estimated 75,673 opioid-related overdose deaths in the 12 months ending in April 2021, an increase from the estimated 56,064 deaths in the prior year CDC(b) 2021.
The rapid rise in opioid-related overdose deaths in recent years is driven by greatly increased exposure to illicitly manufactured fentanyl and fentanyl analogues. Since 2014, these high-potency synthetic opioids have been spreading in the illicit drug supply, often as adulterated or substituted heroin or pressed into counterfeit pills Ciccarone 2021. Illicitly manufactured fentanyl and fentanyl analogues currently account for more than 80% of opioid-related overdose deaths in the United States, increasing from a rate of 11.4 per 100,000 population in 2019 to 17.8 per 100,000 population in 2020 CDC(a) 2021. Additionally, other synthetic additives such as xylazine, a veterinary sedative, have been found with increasing frequency in the drug supply and have contributed to increases in morbidity and mortality Gupta, et al. 2023; Alexander, et al. 2022; Korn, et al. 2021. As of March 2023, fentanyl mixed with xylazine had been found in drugs confiscated in 48 states; the estimated number of drug-poisoning deaths in the United States involving xylazine increased from 260 in 2018 to 3,480 in 2021 Gupta, et al. 2023.
Currently, 3 pharmacologic OUD treatment options are approved by the U.S. Food and Drug Administration: methadone, BUP, and extended-release (XR) naltrexone. Although pharmacologic treatment of OUD reduces overdose mortality by nearly 50%, only 1 out of 5 Americans with past-year OUD had received life-saving treatment in 2021, the most recent year for which data are available Jones(b), et al. 2023; Krawczyk, et al. 2022; Larochelle, et al. 2018; Sordo, et al. 2017. Increased access and linkage to evidence-based OUD treatment is urgently needed given the opioid epidemic’s continued toll on individuals, families, and communities. Implementing and scaling up effective OUD treatment across diverse settings is critical to curbing the opioid epidemic CDC 2022.
Harm reduction as a treatment goal: A traditional goal of OUD treatment is abstinence or long-term cessation of opioid use. However, as fentanyl-fueled overdose deaths increase, harm reduction, including survival, has become an important goal. The mortality benefit of receiving medications for OUD remains strong even if a person intermittently uses opioids during treatment Stone, et al. 2020. In addition, abstinence may not initially be an achievable goal for many individuals; it may take time to achieve. Other goals that can lead to substantial improvements in the health and lives of people with OUD and reduce harm include:
- Reducing the frequency and quantity of opioid use
- Reducing the risk and occurrence of overdose
- Staying engaged in care, which can facilitate prevention, diagnosis, and treatment of other medical and mental health conditions
- Reducing high-risk behaviors, such as injection drug use and sharing of injection equipment, and reducing related complications, such as infection
- Improving quality of life and other social indicators, such as employment and stable housing, and reducing the risk of incarceration
For more information, see NYSDOH AI guideline Substance Use Harm Reduction in Medical Care.
Role of and Requirements for Clinicians
Primary care clinicians in New York State can play an essential role in identifying and treating OUD in their patients. Pharmacologic treatment for OUD in primary care settings reduces nonprescription opioid use and improves retention in treatment Alford, et al. 2011; Altice, et al. 2011; Fiellin, et al. 2011; Lucas, et al. 2010; Cunningham, et al. 2008; Magura, et al. 2007; Mintzer, et al. 2007; Samet, et al. 2001. One study examining BUP treatment for OUD in “real-world” primary care settings reported a 12-month retention rate of 74% among participants treated in a primary care clinic and 49% among those referred to OUD treatment outside of the primary care clinic Lucas, et al. 2010. In addition, a study among individuals with HIV demonstrated that retention in primary care-based BUP treatment is associated with the initiation of antiretroviral therapy and improved viral load suppression Altice, et al. 2011. Similarly, a study among individuals with hepatitis C virus (HCV) reported that retention in primary care-based BUP treatment was associated with a higher likelihood of being evaluated and offered treatment for HCV infection Norton, et al. 2017.
In light of the opioid crisis, all clinicians in New York State, including those who deliver primary care, should be informed about risk reduction and treatment options for OUD.
Federal requirements for clinicians: Federal policies regulate OUD treatment based on the assigned controlled substance classification under the U.S. Department of Justice Drug Enforcement Administration (DEA).
Buprenorphine is a schedule III-controlled substance that has been subject to evolving restrictions. Until 2022, physicians and advanced clinical specialists were required to apply for a separate DEA waiver (commonly known as the “DATA-waiver” or “X-waiver”) to prescribe any formulation of BUP for OUD. In January 2023, the Consolidated Appropriations Act (also known as the Omnibus bill) removed the federal requirement for a DEA waiver to prescribe BUP (see DEA letter on DATA-Waiver Program). With this provision, all clinicians who have a current DEA license to prescribe schedule III-controlled substances can now prescribe BUP for OUD without a patient limit. Effective June 2023, all clinicians who obtain or renew their DEA license will be required to complete 8 hours of training related to substance use (see DEA letter on training requirement). The effect of these policy changes will have to be assessed; however, the elimination of prescriber restrictions is anticipated to increase access to BUP treatment.
In contrast, methadone is a schedule II-controlled substance that can only be dispensed or administered for OUD treatment in specialty opioid treatment programs certified by the Substance Abuse and Mental Health Services Administration (SAMHSA) and single-state agencies for substance use services. Oral naltrexone and XR naltrexone are not scheduled substances and can be prescribed without clinician restrictions.
All 3 medications (BUP, methadone, and naltrexone) can be administered in any acute care setting, although restrictions apply for methadone (see DEA: Narcotic Treatment Program Manual: A Guide to DEA Narcotic Treatment Program Regulations).
Legal Protections for Individuals With OUD
The New York State Human Rights Law (NYSHRL) and the Americans With Disabilities Act (ADA) protect individuals with disabilities from discrimination. Under the NYSHRL and ADA, individuals taking prescribed medical treatment for OUD and those in recovery from OUD are considered disabled (see The Americans with Disabilities Act and the Opioid Crisis: Combating Discrimination Against People in Treatment or Recovery). The NYSHRL and the ADA exclude from protection individuals who are currently using illegal drugs.
Employers and housing providers are prohibited from discriminating against individuals with disabilities under the NYSHRL. Employers are prohibited from denying a job opportunity to a qualified individual, terminating an employee because of a disability, and making inquiries about an individual’s disability, which includes questions about prescribed medical care for OUD. Employers are required to provide reasonable accommodations to assist disabled people in performing their job functions. It is unlawful for housing providers, including skilled nursing facilities, to refuse to house or discriminate against a tenant because they are taking medical treatment for OUD or are in recovery from OUD.
Information about these protections and enforcement of the NYSHRL can be found at the New York State Division of Human Rights.
Telehealth has the potential to reduce barriers to care for individuals with OUD. Historically, under the Ryan Haight Act of 2008, at least 1 in-person medical evaluation of a patient was required before prescribing controlled substances, including BUP. However, at the start of the COVID-19 Public Health Emergency (PHE), the DEA and SAMHSA issued exemptions to allow for BUP initiation through telehealth, including telephonic (audio-only) and video (audio-visual) visits, without first requiring an in-person visit SAMHSA 2020. Practitioners must still adhere to state-specific requirements for telehealth (see NYSDOH Bureau of Narcotic Enforcement). In New York State, both telephonic and video visits for initiating BUP were covered under Medicaid during the COVID-19 PHE Chan, et al. 2022; Cunningham, et al. 2022; NYSDOH 2021. In-person medical evaluation is still required to initiate methadone treatment. The long-term ability to initiate medication for OUD treatment via telehealth remains unclear at this time; PHE exemptions for telehealth have been extended through 2024 while new regulations are under review.
To date, observational studies have found that BUP treatment delivered through telehealth is associated with similar or improved treatment retention and reduced overdose risk compared with BUP treatment delivered through in-person visits Jones(a), et al. 2023; Chan, et al. 2022; Cunningham, et al. 2022; Jones, et al. 2022. Telehealth BUP treatment is feasible and effective for providing OUD treatment for patients who may have limited or no access to in-person clinical care, including patients who live in remote locations, are not stably housed, or are incarcerated Tofighi, et al. 2022; Williams, et al. 2023; Belcher, et al. 2021; Weintraub, et al. 2021. However, rigorous evaluation of telehealth-delivered BUP treatment is still needed to evaluate long-term treatment outcomes, address disparities in access, and implement best practices. Adults who are older, have low income, have limited English language proficiency, are members of ethnic or racial minorities, or who reside in areas with limited or no internet access may not be able to access telehealth services NEJM Catalyst 2020. Access to video visits may also be challenging among people who use drugs who do not have electronic devices, internet or mobile data access, or privacy.
In-person visits for new patients may help establish rapport and facilitate assessment of medical or mental health needs beyond OUD treatment and can be arranged according to an expected timeframe (e.g., within 2 to 4 weeks) without delaying OUD treatment initiation. To ensure treatment access equity, in-person visits should be prioritized for patients who prefer in-person visits or have clinical needs that may benefit from an in-person evaluation (e.g., recent overdose or other acute complications related to OUD, co-occurring SUDs that may increase overdose risk, unstable medical or mental health conditions, persistent concern for diversion). Treatment should not be withheld solely based on patient preference for telehealth or in-person visits.
Who to Treat
Abbreviations: BUP, buprenorphine; ED, emergency department; NLX, naloxone; OUD, opioid use disorder; SUD, substance use disorder; XR, extended-release.
An essential part of initiating and continuing OUD treatment is overdose prevention counseling. Counsel patients to:
- Assume all illicitly manufactured opioids will contain fentanyl or other high-potency synthetic opioids, and that stimulants and counterfeit pills may contain these agents.
- When possible, test drugs with fentanyl test strips, xylazine test strips, or other drug-checking equipment. Online sources include MATTERS (for New York State residents and programs, no charge), DanceSafe, and BTNX. Some NYS Authorized Syringe Exchange Sites may provide fentanyl test strips and other drug-checking systems.
- Avoid using drugs alone. Arrange for someone to check in; use phone- and web-based apps (e.g., Never Use Alone Inc. at 800-484-3731).
- When using any drug, start with a small amount.
- Carry NLX, learn how to use it, and encourage friends and contacts to do the same. The 4 mg NLX nasal spray formulation is available at pharmacies, at NYSDOH-Registered Opioid Overdose Prevention Programs (no charge), and online through MATTERS (for New York State programs and residents, no charge) and NEXT Distro. NLX is covered by New York State Medicaid and the majority of private insurers.
In addition to overdose prevention counseling, clinicians should incorporate harm reduction into OUD treatment planning. For example, all patients who inject opioids or other drugs should be counseled on use of sterile needles and syringes. Licensed pharmacies, healthcare facilities, and clinicians can furnish hypodermic needles or syringes to individuals ≥18 years old without a patient-specific prescription; drug equipment is also available at NYS Authorized Syringe Exchange Sites.
Who to Treat
SUDs, including OUD, have become more widely recognized as chronic conditions McLellan, et al. 2014. OUD is associated with significant and persistent changes in brain structure and function. Naturally occurring endogenous opioids in the brain act on opioid receptors to produce effects on cognition, emotion, pain, sleep, and other domains Maldonado 2010. With repeated exposure to external (exogenous) opioids, the brain’s opioid system may no longer be able to self-regulate Volkow, et al. 2019; Volkow and Koob 2015. When this occurs, tolerance to opioids develops, the brain produces lower levels of endogenous opioids, and a larger dose of exogenous opioids is required to obtain the same effects Volkow, et al. 2016; Williams, et al. 2013. In addition, physical withdrawal symptoms can develop within hours of discontinuing or reducing opioid use Kampman and Jarvis 2015.
Clinicians should offer pharmacologic treatment to adult patients diagnosed with OUD, including patients who are not actively using opioids (see Box 1, below). Pharmacologic treatment is essential in stabilizing and restoring chronic changes in brain structure and function. By alleviating opioid cravings and withdrawal symptoms, pharmacologic treatment can also help individuals focus on improving behavioral components of OUD.
Pharmacologic treatment should be offered to individuals diagnosed with OUD who are not actively using opioids but who are at risk of resuming opioid use. Two important risk factors for return to use and overdose among individuals with OUD are a history of overdose and leaving a controlled setting, such as prison, jail, hospital, or other treatment facilities Olfson, et al. 2018; Binswanger, et al. 2013. Medical care, including hepatitis C virus and HIV screening, prevention, and treatment, as indicated, should be offered to individuals with OUD regardless of their engagement in or adherence to OUD treatment.
|Box 1: DSM-5 Diagnostic Criteria for Opioid Use Disorder [a]||
The DSM-5 describes OUD as a pattern of opioid use that leads to problems or distress, with at least 2 of the criteria below occurring within 12 months. Severity of the OUD is determined by the number of criteria met: mild (2 to 3 criteria); moderate (4 to 5 criteria); and severe (≥6 criteria).
Abbreviations: DSM-5, Diagnostic and Statistical Manual for Mental Disorders, 5th edition; OUD, opioid use disorder.
Use of other substances: Individuals should not be excluded from pharmacologic OUD treatment based on their use of other substances unless there are contraindications to the OUD medications and the risks outweigh the consequences of untreated OUD Payne, et al. 2019; Cunningham(a), et al. 2013; Sullivan, et al. 2011. Studies have demonstrated no significant differences in OUD treatment retention or self-reported opioid use in participants with OUD who used cocaine during the study compared with those who did not Cunningham(a), et al. 2013; Sullivan, et al. 2011. The U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication in 2017 urging caution in withholding methadone or BUP from patients using benzodiazepines or alcohol, noting that the harm of not treating OUD outweighs the risk of adverse events associated with combining the medication. Co-occurring substance use may influence individual treatment plans but should not be the sole reason for excluding patients from pharmacologic OUD treatment.
Psychosocial treatment: Psychosocial treatment interventions for OUD can be useful adjuncts to pharmacologic treatment for some patients; however, clinical trial results have consistently demonstrated that pharmacologic treatment is more effective than nonpharmacologic treatment of OUD in reducing nonprescription opioid use, decreasing overdose risk, improving retention in care, and improving other psychosocial and medical conditions Wakeman, et al. 2020; Fiellin, et al. 2013; Ruetsch, et al. 2012; Tetrault, et al. 2012; Amato(a), et al. 2011; Amato(b), et al. 2011; Weiss, et al. 2011; Humphreys, et al. 2004. A lack of participation in structured psychosocial treatment for OUD should not prompt clinicians to withhold or discontinue pharmacologic treatment for OUD. When psychosocial treatment is mandated by the criminal justice system, child welfare, or other agencies, a clinician’s primary responsibility is to maintain the therapeutic alliance and partner with the patient to address legal mandates.
OUD treatment initiation in the ED: Clinicians in EDs and inpatient hospital settings have many opportunities to reach individuals with OUD who are not linked to care and are not taking OUD treatment medications. Clinicians should initiate pharmacologic OUD treatment in patients who have been treated for an opioid overdose or a complication related to opioid use before they are discharged from acute care or refer patients for OUD treatment. Clinicians in these settings should also dispense or prescribe NLX for patients who use opioids. Studies have demonstrated that initiating BUP treatment in the ED is feasible and cost-effective and can contribute to increased retention in care Wakeman, et al. 2021; Englander, et al. 2019; Busch, et al. 2017; D'Onofrio, et al. 2017; D'Onofrio, et al. 2015; Liebschutz, et al. 2014. The NYSDOH supports MATTERS, an online platform for clinicians in acute care settings to facilitate linkage to care. For further guidance on providing BUP treatment in EDs and hospital settings, please see:
- American College of Emergency Physicians: Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department
- Society of Hospital Medicine: Management of Opioid Use Disorder and Associated Conditions Among Hospitalized Adults
OUD treatment history: Clinicians should obtain a complete history of previous OUD treatment to ensure that the patient’s experiences, preferences, and needs are incorporated into treatment decision-making. When asking patients about prior pharmacologic treatment, clinicians should inquire about tolerance of and success with medication initiation, experience with long-term treatment, adherence challenges, adverse effects, treatment duration, and reasons for stopping treatment SAMHSA(b) 2021; ASAM 2020. Prior experiences with pharmacologic treatment often shape preferences for specific medications; patients who have had negative experiences with 1 medication may prefer to try another Yarborough, et al. 2016. Clinicians should also inquire about self-treatment with nonprescribed medications (including BUP), which is prevalent among individuals trying to reduce opioid use or struggling to access, engage in, or stay engaged in treatment. In observational studies, prior use of nonprescribed BUP is associated with improved treatment retention Williams, et al. 2022; Monico, et al. 2015; Cunningham(b), et al. 2013.
Available pharmacologic treatment: Clinicians should inform patients with OUD about all available pharmacologic treatment options and formulations and engage in shared decision-making about the best setting, medication, and formulation based on the individual patient’s treatment goals, preferences, and insurance coverage.
Currently, 3 medications are approved by the FDA for OUD treatment: methadone, BUP, and XR naltrexone. All 3 medications act on the mu-opioid receptor: methadone as a full opioid agonist, BUP as a partial opioid agonist, and naltrexone as an opioid antagonist. The preferred agents for treatment of OUD are BUP and methadone. Decades of clinical research support the efficacy of opioid agonist medications in reducing nonprescription opioid use and improving retention in treatment among individuals with OUD. BUP and methadone are both associated with up to 50% reduction in risk of all-cause and overdose-related mortality Mattick, et al. 2014; Minozzi, et al. 2011; Ling and Wesson 2003; Mello and Mendelson 1980; Dole and Nyswander 1965. Methadone is associated with higher rates of long-term treatment retention than BUP Degenhardt, et al. 2023, but BUP is more widely available than methadone. Treatment planning, therefore, requires consideration of the relative differences in long-term treatment retention along with a patient’s previous experience, access, and preferences. For a discussion of each medication, see the guideline sections Buprenorphine/Naloxone, Methadone, and Naltrexone.
Many individuals with OUD achieve their treatment goals in outpatient primary care-based settings. When available, specialty OUD treatment settings (e.g., outpatient treatment programs, opioid treatment programs [OTPs]) that provide pharmacologic treatment along with frequent visits, individual and group counseling, and other supportive services may benefit some individuals, including those with co-occurring SUDs, mental health illness requiring intensive treatment, or inadequate psychosocial supports.
Treatment selection based on individual factors: Many individual patient factors influence OUD treatment choice, including prior treatment experience, ease of access, and preferences (see Table 1, below). Pharmacologically, 2 key factors are the patient’s opioid tolerance and co-occurring medical conditions. Patients with low opioid tolerance who wish to initiate opioid agonist treatment may benefit from BUP rather than methadone because, as a partial opioid agonist, BUP carries a lower risk for sedation. Methadone is associated with QT prolongation and respiratory depression, so may not be preferred for patients with cardiac conduction disorders or severe respiratory conditions FDA 2014.
Some patients treated with BUP/NLX for OUD may present clinical challenges that warrant consultation with experts in addiction medicine, obstetrics, adolescent care, pain management, and other medical specialties. Consultation may be necessary when, for instance, managing the care of patients with chronic pain or patients who have ongoing nonprescription opioid use or cravings despite taking the maximum FDA-approved dose (BUP/NLX 24 mg/6 mg daily). The need for BUP doses up to 32 mg in some patients has been recognized Weimer, et al. 2023; Bergen, et al. 2022; Fareed, et al. 2012; SAMHSA 2004. In these and other complex situations, clinicians can contact expert consultants through the NYSDOH AI CEI Line (866-637-2342) and Providers Clinical Support System.
Long-term treatment: Several randomized clinical trials have demonstrated that long-term pharmacologic treatment is more effective at reducing nonprescription opioid use and retaining individuals in treatment than withdrawal management (previously known as “detox”) Fiellin, et al. 2014; Sigmon, et al. 2013; Weiss, et al. 2011; Gruber, et al. 2008; Woody, et al. 2008. In addition, withdrawal management without concurrent use of pharmacologic long-term therapy is associated with an increased risk of return to opioid use, overdose, and death Dowell, et al. 2022; SAMHSA(b) 2021; Bruneau, et al. 2018. A decreased tolerance to opioids developed during withdrawal management increases the risk of opioid overdose Kampman and Jarvis 2015. Despite clear evidence supporting the benefits of long-term pharmacologic treatment, further research to guide the specific duration is needed Dhanda and Salsitz 2021.
Individualized follow-up: After initiating treatment for OUD, follow-up patient contact and scheduling is based on the medication patients are taking and their individual needs. For patients taking BUP/NLX or XR naltrexone in an outpatient primary care setting, following up within 2 weeks of treatment initiation allows the clinician to tailor the treatment plan (e.g., change in medication dosage, addition of support services) to a patient’s needs and provide encouragement. As patients stabilize on BUP/NLX treatment, monthly or at least quarterly follow-up allows for ongoing evaluation to ensure that their goals are being met. For patients taking XR naltrexone, scheduled injections every 28 days are an opportunity to review the treatment plan and address any concerns. For methadone treatment, follow-up frequency is determined by clinical assessment of overdose risk and state and federal regulations governing OTPs.
During long-term treatment, ongoing follow-up is essential for support, encouragement, and modification of the treatment plan as needed. As with the treatment goals for other chronic illnesses, OUD treatment goals are individualized and likely to change over time, and continued engagement in nonjudgmental, health-enabling support can aide in the progression toward healthy goals. Clinicians and patients should discuss, agree on, and revisit OUD treatment goals explicitly and regularly. In general, if patients are not able to meet their goals, increased dosing of medication, more frequent visits, behavioral interventions, and/or mental health assessment and treatment may be warranted.
|Abbreviations: BUP, buprenorphine; CYP450, cytochrome P450; FDA, U.S. Food and Drug Administration; OTP, opioid treatment program; OUD, opioid use disorder; XR, extended-release.|
|Table 1: Considerations When Choosing Buprenorphine or Methadone (Preferred Agents for Opioid Use Disorder Treatment)|
|Effectiveness||Treatment of OUD with BUP or methadone is associated with reducing other opioid use, promoting treatment retention, and reducing all-cause and overdose-related mortality.|
|Patient preferences||May be preferable for patients who are new to pharmacologic OUD treatment, have had previous success with BUP, do not like or want to take methadone, or who have requested this medication.||May be preferable for patients who have had previous success with methadone, do not like or want to take BUP, or who have requested this medication.|
|Setting||Available through various treatment settings, including office-based prescription or specialty OTPs.||
||Opioid withdrawal is not required for initiation.|
||Dose can be increased gradually to suppress opioid cravings and prevent withdrawal, with no maximum dose.|
|Adverse effects and safety||
|Medication interaction||Few clinically significant interactions with medications other than full opioid agonists.||Clinically significant interactions with medications that are metabolized by CYP450 enzymes can occur, leading to increased or decreased effects of methadone.|
|Counseling requirements||Not required unless legally mandated, but clinicians can refer for behavioral therapy and support services.||
|Treatment switch||Switching to XR-BUP or methadone is possible if needed to control opioid cravings and withdrawal despite maximized sublingual BUP dosing.||
BUP/NLX: Preferred Treatment
Abbreviations: BUP, buprenorphine; FDA, U.S. Food and Drug Administration; NLX, naloxone; OUD, opioid use disorder.
Although BUP was developed initially as an analgesic, it was identified several decades ago as an alternative to methadone for OUD treatment Institute of Medicine 1995; Mello and Mendelson 1980; Jasinski, et al. 1978. BUP is a partial opioid agonist with a higher affinity for the mu-opioid receptor than heroin, methadone, and other opioids. It can displace full opioid agonists from mu-opioid receptors and replace them with partial activation. The opioid effect (or “ceiling effect”) of BUP is less intense than the effect produced by methadone or heroin. The high affinity of BUP for the mu-opioid receptor also has protective effects against opioid overdose. If a patient taking BUP/NLX takes a full opioid agonist, BUP will block the other opioid from activating mu-opioid receptors and producing more intensive opioid effects, such as respiratory depression.
Extensive clinical trials and systematic reviews have demonstrated that, compared with placebo, BUP significantly reduces use of nonprescription opioids and improves retention in treatment Mattick, et al. 2014; Amato, et al. 2005; Ling and Wesson 2003; Mattick, et al. 2003. BUP treatment has also been associated with decreased risks of both all-cause and opioid overdose mortality Ma, et al. 2019; Larochelle, et al. 2018; Sordo, et al. 2017; Schuckit 2016. A systematic review of clinical trials and observational studies found that BUP treatment is associated with a lower rate of long-term treatment retention than methadone treatment Degenhardt, et al. 2023. Nonetheless, the relative differences in long-term treatment retention between BUP and methadone should be considered in the context of patient preferences and treatment access, with BUP being more widely available.
Sublingual BUP/NLX: BUP is most commonly available as coformulated BUP/NLX in sublingual films or sublingual tablets, which contain 2 mg to 8 mg of BUP per film or tablet Mattick, et al. 2014; Ling and Wesson 2003. Sublingual BUP/NLX is typically taken as 1 dose or split into 2 to 3 doses daily, depending on the patient’s need for co-occurring pain management. Sublingual BUP/NLX is generally prescribed through community pharmacies for patients to self-administer.
Sublingual BUP: BUP is also available as monoformulated sublingual tablets. However, the BUP/NLX coformulation is recommended over the BUP monoformulation because it is less likely to be misused. When BUP/NLX is taken sublingually, only a negligible amount of NLX, if any, is bioavailable and clinically active. However, when BUP/NLX is injected, NLX is fully bioavailable and will delay the euphoric effects of BUP in individuals who do not already have physical dependence on opioids. Thus, the BUP/NLX coformulation serves as a deterrent to medication misuse. However, most diverted or misused BUP is used for OUD self-treatment and not for euphoria Carroll, et al. 2018. BUP/NLX coformulation is preferred over BUP monoformulation except in patients with hypersensitivity or allergies to NLX, which are extremely rare in clinical experience.
Injectable XR-BUP: Long-acting BUP (XR-BUP) is available as a monthly subcutaneous depot injection Lofwall, et al. 2018. Monthly injectable XR-BUP is typically used with patients who have initiated treatment with a sublingual BUP dosage of 8 mg or higher for a minimum of 7 days, although varying initiation approaches can be used under specialist guidance.
XR-BUP must be obtained through pharmacies that are certified by the XR-BUP manufacturer’s restricted distribution program (see Sublocade REMS [Risk Evaluation and Mitigation Strategy]). The medication is delivered to the prescriber’s practice by the REMS-certified pharmacy in anticipation of a patient’s injection appointment. Clinical programs or healthcare settings that wish to stock XR-BUP onsite must be certified in the XR-BUP manufacturer’s REMS. Brixadi (BUP), another long-acting injection for subcutaneous use, was approved by the FDA in May 2023 for OUD treatment as weekly or monthly injections and will be available in fall 2023.
XR-BUP may be preferred to sublingual BUP/NLX for some patients with OUD, although evidence is just beginning to accrue. XR-BUP can achieve more stable and higher plasma levels than sublingual BUP Radosh, et al. 2022, which may be beneficial for patients with high opioid tolerance or with ongoing opioid withdrawal symptoms or cravings while taking the maximum daily dosage of sublingual BUP. XR-BUP may also improve treatment outcomes for patients who have difficulty adhering to daily dosing. In a randomized clinical trial, patients who initiated XR-BUP before release from jail had higher treatment retention than those receiving BUP/NLX Lee, et al. 2021. An observational study found high treatment retention rates among patients who received XR-BUP, even when most did not have stable housing Peckham, et al. 2021. In another recent randomized trial from Australia, XR-BUP was associated with higher patient satisfaction scores than sublingual BUP/NLX, although this study involved at least weekly visits and observed dosing for BUP/NLX Compton and Volkow 2021.
Insurance coverage: In New York State, as of March 2022, all formulations of BUP prescribed to treat OUD are covered under Medicaid fee-for-service and managed plans (see NYRx Medication Assisted Treatment [MAT] Formulary).
The length of time after a full opioid agonist is stopped and withdrawal starts depends on the opioid’s pharmacologic properties. Known half-lives of full opioid agonists indicate that it may take at least 12 to 24 hours after the last dose of a short-acting opioid and at least 48 to 72 hours after the last dose of a long-acting opioid for a patient to experience opioid withdrawal symptoms.
Opioid withdrawal symptoms include increased heart rate, increased sweating, dilated pupils, restlessness, bone or muscle aches, muscle twitches or tremors, runny nose or tearing, gastrointestinal upset (nausea, vomiting, cramps, diarrhea), anxiety, irritability, goosebumps on skin, hot flushes or chills, and yawning. Clinical tools available to measure the severity of opioid withdrawal include the Clinical Opiate Withdrawal Scale and the Subjective Opiate Withdrawal Scale Wesson and Ling 2003; Handelsman, et al. 1987. Clinicians can offer adjunctive medications, including clonidine, loperamide, and trazodone, to alleviate specific opioid withdrawal symptoms (see Table 2, below).
A patient’s recent opioid use history and review of the NYSDOH Prescription Monitoring Program (PMP) Registry will help clinicians and patients anticipate withdrawal symptoms. Methadone and BUP dispensed from opioid treatment programs (OTPs) will not be included in the PMP.
Precipitated opioid withdrawal: BUP can displace full opioid agonists from mu-opioid receptors and replace them with partial activation. Before starting a patient on BUP/NLX, assess for and inform the patient about the potential for precipitated opioid withdrawal, the symptoms they may experience, and how those symptoms will be managed Cunningham, et al. 2011; Sohler, et al. 2010; Lee, et al. 2009:
- Educate all patients about expected withdrawal symptoms and distinguishing precipitated withdrawal as a sudden worsening of symptoms immediately after BUP/NLX initiation.
- Identify individuals with chronic fentanyl exposure; their risk of precipitated withdrawal may be greater than the risk for patients without chronic fentanyl exposure (see discussion of opioid withdrawal considerations in the context of chronic fentanyl exposure, below).
- Ensure that patients understand the potential severity of precipitated withdrawal symptoms and when to seek medical consultation. Provide patients with a clear plan of response to precipitated withdrawal, including how to contact a clinician.
- If precipitated withdrawal occurs:
- If the patient wants to continue BUP/NLX initiation, advise them to take additional higher doses (e.g., 8 mg/2 mg to 16 mg/4 mg per dose) and provide adjunctive medications for symptom management.
- If the patient decides to stop BUP/NLX initiation, engage the patient in shared decision-making regarding alternative treatment options and initiation strategies.
Opioid withdrawal considerations in the context of chronic fentanyl exposure: The onset and duration of opioid withdrawal may be variable and prolonged in individuals with chronic fentanyl exposure Huhn, et al. 2020. Pharmacologically, the risk of precipitated withdrawal during BUP initiation is higher with fentanyl than with heroin because of fentanyl’s high opioid receptor affinity, lipid solubility, and intrinsic agonist activity Greenwald, et al. 2022. People who regularly use heroin and fentanyl report increasing experiences of precipitated withdrawal and difficulty with standard BUP/NLX initiation, particularly when BUP is initiated within 24 hours of fentanyl use Sue, et al. 2022; Varshneya, et al. 2022; Silverstein, et al. 2019. In contrast, a recent prospective cohort study of patients who presented to the emergency department (ED) for opioid withdrawal reported a very low incidence of precipitated withdrawal after receiving BUP initiation doses of ≥8 mg, despite high rates of heroin and fentanyl use [D’Onofrio, et al. 2023].
Although precipitated withdrawal is a serious concern, BUP can be initiated successfully with effective patient education and support. Continue to offer BUP, discuss patient concerns regarding BUP initiation, and consider an alternative BUP initiation strategy for patients who cannot tolerate opioid withdrawal or who have experienced precipitated withdrawal with standard initiation methods. Alternative strategies include:
- Low-dose BUP with opioid continuation (LDB-OC; previously known as microdosing or micro-induction) with an initial BUP dose of <2 mg and gradual up-titration while continuing full opioid agonist for a limited period; initiation does not require onset of opioid withdrawal (see guideline section Initiating Treatment, below) Cohen, et al. 2022.
- High-dose initiation with an initial BUP dose of >8 mg and rapid up-titration within 1 day; initiation requires onset of opioid withdrawal [D’Onofrio, et al. 2023; Snyder, et al. 2023; Herring, et al. 2019].
Current evidence and expert opinion favor the LDB-OC approach to BUP initiation in the outpatient setting, where patients are often evaluated when they are not in opioid withdrawal or are in mild withdrawal. Published experience with high-dose initiation has been with patients with moderate to severe opioid withdrawal in the ED [D’Onofrio, et al. 2023; Snyder, et al. 2023; Herring, et al. 2019], and further research is needed to guide its use in an ambulatory setting.
|Abbreviations: FDA, U.S. Food and Drug Administration; NSAID, nonsteroidal anti-inflammatory drug.|
|Table 2: Adjunctive Medications to Relieve Acute Opioid Withdrawal Symptoms
Reprinted with permission from Torres-Lockhart, et al. 2022
|Withdrawal Symptom||Medication/Class||Preferred Route/Dosage/Considerations|
|Autonomic hyperactivity, including muscle twitching, hot flushes or chills, restlessness||Clonidine (α-2 agonist)||
|Lofexidine (α-2 agonist)||
|Diarrhea||Loperamide (peripheral μ opioid agonist)||
|Insomnia||Trazodone (sedating anti-depressant)||Oral, 25 to 100 mg once daily at night|
|Doxepin (sedating anti-depressant)||Oral, 10 to 50 mg once daily at night|
|Muscle aches, joint pain, headache||Ibuprofen (NSAID)||
|Acetaminophen (aniline analgesic)||
|Anxiety, restlessness||Diphenhydramine (antihistamine)||
Setting: Home-based (unobserved) and office-based (observed) initiation of BUP/NLX treatment are safe and effective Cunningham, et al. 2011; Gunderson, et al. 2010; Sohler, et al. 2010; Lee, et al. 2009. The choice of setting is based on the patient’s comfort, preferences, and previous experience, as well as a clinician’s experience and support. The primary concern during initiation is precipitating opioid withdrawal, which can be deeply uncomfortable but can be ameliorated outside of an observed clinical setting (see guideline section Opioid Withdrawal, above). Individuals with OUD who are not in treatment may experience withdrawal symptoms regularly between doses of opioids over many years; patients’ familiarity with opioid withdrawal may be leveraged to help counsel and support them through home-based initiation. A patient’s preferences in managing their medications, including dividing BUP/NLX tablets or films into smaller doses, and access to telehealth for frequent check-ins can facilitate successful home-based initiation. Alternatively, observed initiation may be preferable for patients who do not have a safe space to prepare and store medications or manage potential withdrawal symptoms.
Standard initiation: The goals of treatment initiation are to control the patient’s opioid cravings, reduce withdrawal symptoms, and reduce nonprescription opioid use. With the standard approach to BUP/NLX initiation, the patient should experience mild to moderate withdrawal before the first dose is administered (see Table 3, below). The initial dose of BUP/NLX is typically 2 mg/0.5 mg to 4 mg/1 mg and is titrated every 1 to 2 hours in increments of 2 mg/0.5 mg to 4 mg/1 mg until the patient’s withdrawal symptoms improve. Advise patients to allow time (e.g., a few hours) for opioid withdrawal symptoms to improve after BUP/NLX initiation. The total dose of BUP/NLX taken on day 1 should be administered on day 2, with incremental dose increases if the patient continues to experience opioid withdrawal symptoms or cravings. The BUP/NLX dose typically stabilizes between days 2 to 7 during the standard initiation process, and the maximum dose of BUP/NLX is typically 24 mg/6 mg per day. For patient education on initiation, see the Addiction Training Institute: A Guide for Patients Beginning Buprenorphine Treatment.
Treatment may be initiated with higher doses of BUP/NLX (e.g., 4 mg/1 mg to 8 mg/2 mg) if a patient has prior experience with BUP/NLX, with dose titration up to BUP/NLX 24 mg/6 mg on the first day. Patients who are transitioning from long-acting opioids, such as methadone, to BUP/NLX may be at higher risk for complications during the standard initiation process Whitley, et al. 2010. Consulting with an experienced clinician may help determine the optimal initiation approach.
Low-dose BUP with opioid continuation (LDB-OC): This approach, which does not require waiting for onset of opioid withdrawal, may be appropriate for patients who are unable to tolerate waiting for onset of opioid withdrawal, have experienced precipitated withdrawal with standard initiation methods, are receiving full opioid agonist treatment for acute or chronic pain, or are receiving methadone treatment for OUD. Treatment may be initiated with a very low dose of BUP (e.g., 0.2 mg to 0.5 mg), followed by small incremental dose increases over 4 to 10 days. Patients can continue to take other full opioid agonists, including nonprescribed opioids until a therapeutic level of BUP is reached (typically >8 mg). Case reports on use in nonpregnant adults indicate that low-dose initiation is well tolerated and may reduce severity of withdrawal symptoms during BUP/NLX initiation Cohen, et al. 2022; Adams, et al. 2021; Ahmed, et al. 2021; Hämmig, et al. 2016.
Although high-quality evidence comparing the effectiveness of standard versus low-dose initiation strategies is not yet available to guide clinical care, different methods for LDB-OC have been described, with starting doses varying by availability of formulations and treatment settings. Table 4, below, provides an example of an outpatient protocol based on clinical review articles and the author’s experience at Montefiore Medical Center Cohen, et al. 2022; Peterkin, et al. 2022. Protocols can be individualized and can be shorter or longer in duration based on patients’ comfort and clinicians’ experience. Clinicians may wish to seek expert consultation in individualizing a treatment plan.
There are no strong data available to help patients use nonprescribed opioids safely during the BUP/NLX initiation process. A discussion of treatment should address the risks of ongoing use and strategies to maximize safety, including safer use practices and overdose prevention (see NYSDOH AI guideline Substance Use Harm Reduction in Medical Care).
For patients taking methadone and planning to switch to BUP, safely continuing methadone treatment during low-dose BUP/NLX initiation can be done via coordination of care with the OTP. Some OTPs can oversee the low-dose initiation process before transferring BUP treatment to primary care settings.
Clear instructions to guide a patient through low-dose BUP/NLX initiation should include: 1) when and how to split films or tablets; 2) how to manage daily dosing changes; 3) how much and how long to continue use of full opioid agonists; and 4) when and how to follow-up on concerns during the initiation process. Low-dose initiation requires splitting the BUP/NLX 2 mg/0.5 mg films or tablets. A quarter of a film or tablet is a 0.5 mg BUP dose; half of a film or tablet is a 1 mg BUP dose. When possible, arranging for a pill box during an office visit or coordinating with a pharmacy to blister pack BUP/NLX can be very beneficial.
Maximum daily BUP/NLX dose: Although the maximum daily FDA-approved dose of sublingual BUP/NLX is 24 mg/6 mg, a higher dose may be beneficial for some patients, including those with a high degree of opioid dependence who continue to experience withdrawal symptoms or cravings Grande, et al. 2023; Weimer, et al. 2023; Bergen, et al. 2022; Fareed, et al. 2012; SAMHSA 2004.
Before increasing the BUP/NLX dose beyond 24 mg/6 mg, clinicians should ensure patients are taking the medication as scheduled and taking it properly, i.e., allowing it to fully dissolve under the tongue rather than swallowing. Clinicians can also counsel patients to split the BUP/NLX dose to twice or 3 times daily dosing. As indicated, clinicians should offer medication and psychosocial treatment to manage specific symptoms that may persist after acute opioid withdrawal (also referred to as protracted withdrawal or post-acute withdrawal syndrome), including anxiety, depression, and sleep disturbances (see SAMHSA: Substance Abuse Treatment Advisory: Protracted Withdrawal) SAMHSA 2010. Dose increases above the FDA-approved maximum require close monitoring for treatment effectiveness and safety; documentation explaining the clinical rationale for such dose increases is advised. Other strategies for managing continued opioid withdrawal symptoms or cravings include the use of injectable XR-BUP or referral for methadone treatment, if available. Consulting with or referring the patient for consultation with an experienced substance use clinician may be needed to optimize the next steps of OUD treatment.
Adverse effects: Adverse effects associated with BUP/NLX are oral hypoesthesia (sensitivity), glossodynia (burning sensation in the mouth), oral mucosal erythema, headache, nausea, vomiting, hyperhidrosis (excessive sweating), constipation, signs and symptoms of withdrawal, insomnia, pain, and peripheral edema FDA 2010. The bitter or bad taste of BUP/NLX is a frequent patient complaint in clinical practice; patients can be counseled to spit out their saliva or take a strong mint after BUP/NLX is fully dissolved. See prescribing information for full details.
|Abbreviations: BUP, buprenorphine; DEA, Drug Enforcement Administration; FDA, U.S. Food and Drug Administration; LDB-OC, low-dose buprenorphine with opioid continuation; NLX, naloxone; OUD, opioid use disorder; REMS, Risk Evaluation and Mitigation Strategy; SAMHSA, Substance Abuse and Mental Health Services Administration; XR, extended-release.
|Table 3: Buprenorphine/Naloxone for Treatment of Opioid Use Disorder in Nonpregnant Adults [a,b,c]|
|Formulations and Mechanism of Action||Dosing (individualize as indicated)||Considerations for Use|
|BUP/NLX sublingual film and tablet (multiple brands; see Medscape: Buprenorphine/Naloxone for more information)
Mechanism: Partial opioid agonist
|BUP monotherapy sublingual tablets (multiple brands)||See BUP/NLX dosing, above.||See BUP/NLX considerations for use, above.|
|XR-BUP subcutaneous depot injections (Sublocade) [e,f]
Mechanism: Partial opioid agonist
|Abbreviations: BUP, buprenorphine; NLX, naloxone.
|Table 4: Example Protocol for Outpatient Low-Dose Buprenorphine With Opioid Continuation [a,b]|
|Day||Dosing of BUP [c]||Total Daily Dose of BUP||Full Opioid Agonist Use/Administration|
|1||0.5 mg once daily||0.5 mg||Continue|
|2||0.5 mg twice daily||1 mg||Continue|
|3||1 mg twice daily||2 mg||Continue|
|4||2 mg twice daily||3 mg||Continue|
|5||3 mg twice daily||6 mg||Continue|
|6||4 mg twice daily||8 mg||Continue|
|7||8 mg AM and 4 mg PM||12 mg||STOP|
Approach to Tapering
There is no ideal duration for BUP/NLX treatment for OUD; long-term pharmacologic treatment is recommended over withdrawal management (previously known as “detox”); see guideline section Treatment Considerations > Treatment Options. Studies published to date have not identified clear modifiable factors that predict optimal outcomes with BUP treatment. Based on committee expert experience, patients treated with BUP long-term in the primary care setting can successfully manage OUD for a decade or more without resuming use of nonprescription opioids.
If a patient has a clear desire to taper and stop BUP/NLX treatment, the clinician should ascertain the patient’s reasons for doing so. Some patients may associate long-term OUD treatment with the stigma of taking an opioid agonist Bozinoff, et al. 2018. If stigma is a predominant factor in a patient’s desire to stop BUP/NLX treatment, education regarding the chronic nature of OUD may help the patient accept the need for long-term medical management.
If a patient decides to discontinue BUP/NLX treatment, clinicians should provide harm reduction counseling and NLX to reduce the risks of recurrence of use and overdose. Counsel patients that with an interruption or decrease in use, their opioid tolerance has decreased, which increases the risk of overdose, and emphasize that they can restart pharmacologic treatment at any time.
Offer a slow taper over several months, and provide NLX at each encounter. There are limited data to guide the speed and duration of a BUP/NLX taper. In a retrospective cohort study, BUP/NLX tapering undertaken after at least 1 year of BUP treatment and a slow rate of taper (mean rate of ≤2 mg dose decrease per month over the taper period) were associated with reduced risk of opioid overdose Bozinoff, et al. 2022. A mean taper rate of ≤2 mg per month over the taper period was also associated with a reduced risk of return to opioid use Bozinoff, et al. 2022. In general, a reasonable approach is to reduce the daily dose of BUP/NLX by 10% to 20% per month. Providing a slow taper is likely to lead to less severe opioid withdrawal symptoms and may be easier for patients to tolerate than a rapid taper.
Methadone: Preferred Treatment
Abbreviations: BUP, buprenorphine; NLX, naloxone; OTP, opioid treatment program; OUD, opioid use disorder.
Efficacy: Methadone is a full opioid agonist of the mu-opioid receptor. Full activation results in commonly known opioid effects, such as pain reduction, a sense of well-being or pleasure, and respiratory depression.
Clinical use of methadone for the treatment of OUD began in the 1960s Jaffe, et al. 1969; Dole and Nyswander 1965, and numerous studies have demonstrated methadone’s effectiveness in reducing nonprescription opioid use and improving retention in care compared with no treatment Kampman and Jarvis 2015; Mattick, et al. 2014; Mattick, et al. 2009. Methadone treatment has been associated with improvements in survival Sordo, et al. 2017; Soyka, et al. 2011, reduction in HIV and hepatitis C virus acquisition and transmission Lucas, et al. 2010, improvement in quality of life Giacomuzzi, et al. 2003, improvement in birth-parent/fetal outcomes Minozzi, et al. 2008, and reduction in criminal activity Lind, et al. 2005.
Specialty OTPs: Methadone treatment for OUD is available only in specialty OTPs regulated by federal and state agencies. Regulations limit the number of patients that can be treated in each program and require observed dosing until patients are granted take-home doses based on established criteria. These restrictions have contributed to reduced access to methadone treatment for many individuals with OUD SAMHSA(a) 2019; SAMHSA(b) 2019. Effective for 1 year after the end of the COVID-19 Public Health Emergency, OTPs have increased flexibility to provide unsupervised take-home doses of methadone, potentially up to 28-day supplies, depending on the patient’s time in treatment and the OTP clinician’s assessment of therapeutic risks and benefits SAMHSA 2023. Flexibility in methadone take-home policies has not been made permanent, but studies show increased treatment engagement and patient satisfaction and no increases in overdose and diversion with take-home medication SAMHSA 2023; Hoffman, et al. 2022; Amram, et al. 2021.
Clinicians should be aware of OUD treatment options in the patients’ community and refer patients to an OTP when appropriate (see SAMHSA: Opioid Treatment Program Directory and NYS OASAS Treatment Availability Dashboard).
Because federal policies provide enhanced protection for individuals receiving substance use disorder (SUD) treatment (e.g., Code of Federal Regulations > Confidentiality of Substance Use Disorder Patient Records), clinicians should be aware that methadone dispensed from the OTP will not appear in the PMP; clinicians who are not affiliated with the OTP must also provide written patient consent to obtain information about treatment from the OTP. Communication between clinicians inside and outside of OTPs is important for many reasons, such as increased likelihood of identifying and managing potential drug-drug interactions and adverse effects (including central nervous system suppression) and overall health management.
Patient selection: Individuals who have a high tolerance for opioids or who have continued cravings while taking maximal doses of BUP/NLX may benefit from methadone, which is a full opioid agonist, to achieve optimal outcomes (see Table 1: Considerations When Choosing Buprenorphine or Methadone [Preferred Agents for Opioid Use Disorder Treatment]). Individuals with comorbidities, such as unstable serious mental illness or other untreated SUDs (e.g., alcohol use disorder or benzodiazepine use disorder), may benefit from an intensive treatment setting to optimize access to supportive services.
Adverse effects: Adverse effects associated with the use of methadone include constipation, lightheadedness, dizziness, sedation, nausea, vomiting, and sweating. Methadone use has been associated with life-threatening respiratory depression and QT prolongation FDA 2014. See prescribing information for full details.
Naltrexone: Alternative Treatment
Abbreviations: BUP, buprenorphine; NLX, naloxone; OUD, opioid use disorder; XR, extended-release.
Naltrexone is an opioid antagonist (inhibitor) that binds to the mu-opioid receptor, causes no opioid effects, and fully blocks opioid agonists (heroin, methadone, and other opioids) from attaching to the mu-opioid receptor and causing opioid effects Bisaga, et al. 2018. Oral naltrexone is not approved by the U.S. Food and Drug Administration (FDA) for OUD treatment, although it is approved for the treatment of alcohol use disorder (see NYSDOH AI guideline Treatment of Alcohol Use Disorder > Preferred Pharmacologic Treatment).
Clinicians can use oral naltrexone to confirm that patients have been abstinent from opioids, to test whether patients can tolerate naltrexone before administering an XR injection, or to supplement XR naltrexone if patients experience cravings or withdrawal symptoms during the 28 days between naltrexone injections.
The long-acting injectable naltrexone formulation (XR naltrexone) became available in 2010. Studies have demonstrated that XR naltrexone is more effective than placebo for OUD treatment Tiihonen, et al. 2012; Gastfriend 2011; Comer, et al. 2006, but only 2 randomized trials directly comparing BUP/NLX and XR naltrexone have been published to date Lee, et al. 2018; Tanum, et al. 2017. In 1 study conducted in the United States, participants randomized to receive BUP/NLX treatment had better outcomes, including higher treatment initiation rates and lower opioid return-to-use rates, than those randomized to receive XR naltrexone Lee, et al. 2018. In the other study, conducted in Norway, retention in treatment and the level of opioid use was similar in participants taking BUP/NLX and XR naltrexone Tanum, et al. 2017. Neither of these studies was conducted in a primary care setting; the U.S. study was conducted in community-based inpatient settings with outpatient follow-up, and the study in Norway was conducted in addiction clinics, where BUP/NLX was administered daily.
Furthermore, the risk of overdose among participants receiving XR naltrexone in the U.S. randomized controlled trial discussed above was nearly 4 times higher than the risk of overdose among those receiving BUP/NLX Ajazi, et al. 2022. Three large studies also found that XR naltrexone was not associated with decreased risk of overdose or all-cause mortality Wakeman, et al. 2020; Morgan, et al. 2019; Larochelle, et al. 2018. Additionally, a large observational study found that participants with OUD who were treated with XR naltrexone were twice as likely to discontinue treatment after 30 days than those receiving BUP/NLX Morgan, et al. 2018. In 2019, the FDA issued a warning letter regarding the increased risk of overdose following cessation of naltrexone treatment for OUD FDA 2019.
Who to Treat
Injectable XR naltrexone may be considered if BUP or methadone is not accessible or desired. Methadone and BUP are preferred over XR naltrexone because of the survival benefit associated with opioid agonist treatment among individuals with OUD Wakeman, et al. 2020; Morgan, et al. 2019; Larochelle, et al. 2018. In particular, BUP/NLX is currently preferred over XR naltrexone based on the results of clinical trials Lee, et al. 2018; Tanum, et al. 2017 (see discussion above), the practical challenges of initiating and maintaining XR naltrexone treatment, and the low number of patients who choose XR naltrexone over other options Brooklyn and Sigmon 2017.
Initiating treatment with XR naltrexone requires patients to be fully withdrawn from opioids, which is difficult for many patients, particularly in outpatient settings. In the U.S. randomized controlled trial described above, 28% of participants assigned to XR naltrexone did not complete the initiation phase versus only 6% assigned to BUP/NLX Lee, et al. 2018. The initiation process is likely part of the reason few patients choose to take XR naltrexone. In real-world practice, of 3,639 patients with OUD being treated in Vermont (where all treatment options are generally available), 2,565 were taking methadone, 1,055 were taking BUP, and 2 were taking XR naltrexone Brooklyn and Sigmon 2017.
Clinicians should emphasize the need for adherence to XR naltrexone for OUD treatment. Clinical trials evaluating XR naltrexone for OUD treatment have demonstrated that adherence is essential to achieving a reduction in nonprescription opioid use and improving retention in treatment Jarvis, et al. 2018; Lee, et al. 2018; Tanum, et al. 2017. The initial clinical studies with XR naltrexone were performed among highly motivated individuals who were at risk of losing their jobs because of OUD Saxon, et al. 2018. A registry study found that factors associated with longer-term adherence were employment at baseline, private health insurance, normal mental status/minimal mental illness, school attendance, and less prior drug use Saxon, et al. 2018.
Before initiating XR naltrexone, inform patients of the following:
- There is a risk of prolonged opioid withdrawal if opioids are still in the patient’s system when XR naltrexone is administered.
- Unlike BUP and methadone, XR naltrexone will not relieve withdrawal symptoms.
- There may be an increased risk of overdose if opioids are used after stopping treatment with XR naltrexone or toward the end of the 28-day dosing interval. Although overdose can occur when opioids are used after stopping any medication for OUD treatment, the risk is particularly high after stopping XR naltrexone, relative to BUP or methadone, because of the substantial reduction in opioid tolerance with XR naltrexone.
Prescribing information indicates that individuals should be abstinent from opioids for approximately 7 to 14 days before initiating XR naltrexone FDA 2013: 7 days for patients using short-acting opioids and 14 days for patients using long-acting opioids (e.g., methadone, XR formulations). During this period of opioid abstinence, individuals with OUD will experience moderate to severe withdrawal symptoms.
To confirm that an adequate length of time has passed since last opioid use (“washout period”), clinicians should perform an NLX challenge by administering intranasal NLX as available and observing the reaction (see Table 5, below). In individuals with recent opioid use, this may precipitate opioid withdrawal. If intranasal NLX is not available, consider a challenge with oral naltrexone, starting with a low dose (e.g., quarter of a 50 mg tablet or as available). If a patient is already taking oral naltrexone, an NLX challenge is not necessary.
In patients confirmed to have an adequate washout period but who have not previously tried naltrexone, a brief regimen of oral naltrexone can be used to confirm medication tolerance before administering the long-acting injectable formulation (see Table 5, below). Oral naltrexone is not approved by the FDA for OUD treatment, but it is used to initiate the treatment cycle for XR naltrexone. Alternatively, to shorten the initiation period for XR naltrexone, very low doses of naltrexone can be initiated in combination with a BUP taper without requiring a full opioid washout period Bisaga, et al. 2018. Oral naltrexone doses can be gradually titrated up to full blocking doses within 7 days to demonstrate naltrexone tolerance.
Once it is confirmed that a patient can tolerate naltrexone, an injection of XR naltrexone (380 mg intragluteal) may be administered every 28 days. It can be administered every 21 days if patients have breakthrough cravings. If injectable XR naltrexone is not immediately available, or if patients have breakthrough cravings during the cycle, oral naltrexone may also be taken.
Adverse effects: Adverse effects associated with XR naltrexone use include protracted withdrawal, nausea, vomiting, injection site reactions (including induration, pruritus, nodules, and swelling), muscle cramps, dizziness or syncope, somnolence or sedation, anorexia, decreased appetite, or other appetite disorders FDA 2022. See prescribing information for full details.
|Abbreviations: BUP, buprenorphine; NLX, naloxone; OUD, opioid use disorder; XR, extended-release.
|Table 5: Extended-Release Naltrexone for Treatment of Opioid Use Disorder in Nonpregnant Adults [a,b]|
|Formulation and Mechanism of Action||Dosing||Considerations for Use|
|XR naltrexone (Vivitrol)
Mechanism: Opioid antagonist
|Initial and long-term treatment (intragluteal injections): 380 mg every 28 days
Pain Management for Patients With OUD
Individuals with opioid use disorder (OUD) often have co-occurring pain, including acute and chronic pain. In general, patients who are taking buprenorphine or methadone for OUD treatment should continue to take their long-term treatment dose while optimizing nonopioid medications and nonpharmacologic treatments. Temporarily increasing the buprenorphine/naloxone or methadone dose or splitting the dosing frequency may be effective for managing acute pain; the addition of a short-acting full-agonist opioid can be considered for management of moderate to severe acute pain ASAM 2020. When adding a full-agonist opioid analgesic, patients will likely need a higher dose than opioid-naive patients to achieve adequate analgesia ASAM 2020.
Detailed recommendations for pain management for patients with OUD are beyond the scope of this guideline. Clinicians are advised to consult the American Society of Addiction Medicine National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update > Special Populations: Individuals With Pain.
|ALL RECOMMENDATIONS: TREATMENT OF OPIOID USE DISORDER|
Who to Treat
BUP/NLX: Preferred Treatment
Methadone: Preferred Treatment
Naltrexone: Alternative Treatment
Abbreviations: BUP, buprenorphine; ED, emergency department; FDA, U.S. Food and Drug Administration; NLX, naloxone; OTP, opioid treatment program; OUD, opioid use disorder; SUD, substance use disorder; XR, extended-release.
Date of current publication: August 8, 2023
Lead authors: Jessica Rodrigues, MS; Jessica M. Atrio, MD, MSc; and Johanna L. Gribble, MA
Writing group: Steven M. Fine, MD, PhD; Rona M. Vail, MD; Samuel T. Merrick, MD; Asa E. Radix, MD, MPH, PhD; Christopher J. Hoffmann, MD, MPH; Charles J. Gonzalez, MD
Committee: Medical Care Criteria Committee
Date of original publication: August 8, 2023
Throughout its guidelines, the New York State Department of Health (NYSDOH) AIDS Institute (AI) Clinical Guidelines Program recommends “shared decision-making,” an individualized process central to patient-centered care. With shared decision-making, clinicians and patients engage in meaningful dialogue to arrive at an informed, collaborative decision about a patient’s health, care, and treatment planning. The approach to shared decision-making described here applies to recommendations included in all program guidelines. The included elements are drawn from a comprehensive review of multiple sources and similar attempts to define shared decision-making, including the Institute of Medicine’s original description [Institute of Medicine 2001]. For more information, a variety of informative resources and suggested readings are included at the end of the discussion.
The benefits to patients that have been associated with a shared decision-making approach include:
- Decreased anxiety [Niburski, et al. 2020; Stalnikowicz and Brezis 2020]
- Increased trust in clinicians [Acree, et al. 2020; Groot, et al. 2020; Stalnikowicz and Brezis 2020]
- Improved engagement in preventive care [McNulty, et al. 2022; Scalia, et al. 2022; Bertakis and Azari 2011]
- Improved treatment adherence, clinical outcomes, and satisfaction with care [Crawford, et al. 2021; Bertakis and Azari 2011; Robinson, et al. 2008]
- Increased knowledge, confidence, empowerment, and self-efficacy [Chen, et al. 2021; Coronado-Vázquez, et al. 2020; Niburski, et al. 2020]
Collaborative care: Shared decision-making is an approach to healthcare delivery that respects a patient’s autonomy in responding to a clinician’s recommendations and facilitates dynamic, personalized, and collaborative care. Through this process, a clinician engages a patient in an open and respectful dialogue to elicit the patient’s knowledge, experience, healthcare goals, daily routine, lifestyle, support system, cultural and personal identity, and attitudes toward behavior, treatment, and risk. With this information and the clinician’s clinical expertise, the patient and clinician can collaborate to identify, evaluate, and choose from among available healthcare options [Coulter and Collins 2011]. This process emphasizes the importance of a patient’s values, preferences, needs, social context, and lived experience in evaluating the known benefits, risks, and limitations of a clinician’s recommendations for screening, prevention, treatment, and follow-up. As a result, shared decision-making also respects a patient’s autonomy, agency, and capacity in defining and managing their healthcare goals. Building a clinician-patient relationship rooted in shared decision-making can help clinicians engage in productive discussions with patients whose decisions may not align with optimal health outcomes. Fostering open and honest dialogue to understand a patient’s motivations while suspending judgment to reduce harm and explore alternatives is particularly vital when a patient chooses to engage in practices that may exacerbate or complicate health conditions [Halperin, et al. 2007].
Options: Implicit in the shared decision-making process is the recognition that the “right” healthcare decisions are those made by informed patients and clinicians working toward patient-centered and defined healthcare goals. When multiple options are available, shared decision-making encourages thoughtful discussion of the potential benefits and potential harms of all options, which may include doing nothing or waiting. This approach also acknowledges that efficacy may not be the most important factor in a patient’s preferences and choices [Sewell, et al. 2021].
Clinician awareness: The collaborative process of shared decision-making is enhanced by a clinician’s ability to demonstrate empathic interest in the patient, avoid stigmatizing language, employ cultural humility, recognize systemic barriers to equitable outcomes, and practice strategies of self-awareness and mitigation against implicit personal biases [Parish, et al. 2019].
Caveats: It is important for clinicians to recognize and be sensitive to the inherent power and influence they maintain throughout their interactions with patients. A clinician’s identity and community affiliations may influence their ability to navigate the shared decision-making process and develop a therapeutic alliance with the patient and may affect the treatment plan [KFF 2023; Greenwood, et al. 2020]. Furthermore, institutional policy and regional legislation, such as requirements for parental consent for gender-affirming care for transgender people or insurance coverage for sexual health care, may infringe upon a patient’s ability to access preventive- or treatment-related care [Sewell, et al. 2021].
Health equity: Adapting a shared decision-making approach that supports diverse populations is necessary to achieve more equitable and inclusive health outcomes [Castaneda-Guarderas, et al. 2016]. For instance, clinicians may need to incorporate cultural- and community-specific considerations into discussions with women, gender-diverse individuals, and young people concerning their sexual behaviors, fertility intentions, and pregnancy or lactation status. Shared decision-making offers an opportunity to build trust among marginalized and disenfranchised communities by validating their symptoms, values, and lived experience. Furthermore, it can allow for improved consistency in patient screening and assessment of prevention options and treatment plans, which can reduce the influence of social constructs and implicit bias [Castaneda-Guarderas, et al. 2016].
Clinician bias has been associated with health disparities and can have profoundly negative effects [FitzGerald and Hurst 2017; Hall, et al. 2015]. It is often challenging for clinicians to recognize and set aside personal biases and to address biases with peers and colleagues. Consciously or unconsciously, negative or stigmatizing assumptions are often made about patient characteristics, such as race, ethnicity, gender, sexual orientation, mental health, and substance use [Avery, et al. 2019; van Boekel, et al. 2013; Livingston, et al. 2012]. With its emphasis on eliciting patient information, a shared decision-making approach encourages clinicians to inquire about patients’ lived experiences rather than making assumptions and to recognize the influence of that experience in healthcare decision-making.
Stigma: Stigma may prevent individuals from seeking or receiving treatment and harm reduction services [Tsai, et al. 2019]. Among people with HIV, stigma and medical mistrust remain significant barriers to healthcare utilization, HIV diagnosis, and medication adherence and can affect disease outcomes [Turan, et al. 2017; Chambers, et al. 2015], and stigma among clinicians against people who use substances has been well-documented [Stone, et al. 2021; Tsai, et al. 2019; van Boekel, et al. 2013]. Sexual and reproductive health, including strategies to prevent HIV transmission, acquisition, and progression, may be subject to stigma, bias, social influence, and violence.
|SHARED DECISION-MAKING IN HIV CARE|
Resources and Suggested Reading
In addition to the references cited below, the following resources and suggested reading may be useful to clinicians.
Acree ME, McNulty M, Blocker O, et al. Shared decision-making around anal cancer screening among black bisexual and gay men in the USA. Cult Health Sex 2020;22(2):201-16. [PMID: 30931831]
Avery JD, Taylor KE, Kast KA, et al. Attitudes toward individuals with mental illness and substance use disorders among resident physicians. Prim Care Companion CNS Disord 2019;21(1):18m02382. [PMID: 30620451]
Bertakis KD, Azari R. Patient-centered care is associated with decreased health care utilization. J Am Board Fam Med 2011;24(3):229-39. [PMID: 21551394]
Castaneda-Guarderas A, Glassberg J, Grudzen CR, et al. Shared decision making with vulnerable populations in the emergency department. Acad Emerg Med 2016;23(12):1410-16. [PMID: 27860022]
Chambers LA, Rueda S, Baker DN, et al. Stigma, HIV and health: a qualitative synthesis. BMC Public Health 2015;15:848. [PMID: 26334626]
Chen CH, Kang YN, Chiu PY, et al. Effectiveness of shared decision-making intervention in patients with lumbar degenerative diseases: a randomized controlled trial. Patient Educ Couns 2021;104(10):2498-2504. [PMID: 33741234]
Coronado-Vázquez V, Canet-Fajas C, Delgado-Marroquín MT, et al. Interventions to facilitate shared decision-making using decision aids with patients in primary health care: a systematic review. Medicine (Baltimore) 2020;99(32):e21389. [PMID: 32769870]
Coulter A, Collins A. Making shared decision-making a reality: no decision about me, without me. 2011. https://www.kingsfund.org.uk/sites/default/files/Making-shared-decision-making-a-reality-paper-Angela-Coulter-Alf-Collins-July-2011_0.pdf
Crawford J, Petrie K, Harvey SB. Shared decision-making and the implementation of treatment recommendations for depression. Patient Educ Couns 2021;104(8):2119-21. [PMID: 33563500]
FitzGerald C, Hurst S. Implicit bias in healthcare professionals: a systematic review. BMC Med Ethics 2017;18(1):19. [PMID: 28249596]
Greenwood BN, Hardeman RR, Huang L, et al. Physician-patient racial concordance and disparities in birthing mortality for newborns. Proc Natl Acad Sci U S A 2020;117(35):21194-21200. [PMID: 32817561]
Groot G, Waldron T, Barreno L, et al. Trust and world view in shared decision making with indigenous patients: a realist synthesis. J Eval Clin Pract 2020;26(2):503-14. [PMID: 31750600]
Hall WJ, Chapman MV, Lee KM, et al. Implicit racial/ethnic bias among health care professionals and its influence on health care outcomes: a systematic review. Am J Public Health 2015;105(12):e60-76. [PMID: 26469668]
Halperin B, Melnychuk R, Downie J, et al. When is it permissible to dismiss a family who refuses vaccines? Legal, ethical and public health perspectives. Paediatr Child Health 2007;12(10):843-45. [PMID: 19043497]
Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. 2001. https://www.ncbi.nlm.nih.gov/books/NBK222274/
KFF. Key data on health and health care by race and ethnicity. 2023 Mar 15. https://www.kff.org/racial-equity-and-health-policy/report/key-data-on-health-and-health-care-by-race-and-ethnicity/ [accessed 2023 May 19]
Livingston JD, Milne T, Fang ML, et al. The effectiveness of interventions for reducing stigma related to substance use disorders: a systematic review. Addiction 2012;107(1):39-50. [PMID: 21815959]
McNulty MC, Acree ME, Kerman J, et al. Shared decision making for HIV pre-exposure prophylaxis (PrEP) with black transgender women. Cult Health Sex 2022;24(8):1033-46. [PMID: 33983866]
Niburski K, Guadagno E, Abbasgholizadeh-Rahimi S, et al. Shared decision making in surgery: a meta-analysis of existing literature. Patient 2020;13(6):667-81. [PMID: 32880820]
Parish SJ, Hahn SR, Goldstein SW, et al. The International Society for the Study of Women’s Sexual Health process of care for the identification of sexual concerns and problems in women. Mayo Clin Proc 2019;94(5):842-56. [PMID: 30954288]
Robinson JH, Callister LC, Berry JA, et al. Patient-centered care and adherence: definitions and applications to improve outcomes. J Am Acad Nurse Pract 2008;20(12):600-607. [PMID: 19120591]
Scalia P, Durand MA, Elwyn G. Shared decision-making interventions: an overview and a meta-analysis of their impact on vaccine uptake. J Intern Med 2022;291(4):408-25. [PMID: 34700363]
Sewell WC, Solleveld P, Seidman D, et al. Patient-led decision-making for HIV preexposure prophylaxis. Curr HIV/AIDS Rep 2021;18(1):48-56. [PMID: 33417201]
Stalnikowicz R, Brezis M. Meaningful shared decision-making: complex process demanding cognitive and emotional skills. J Eval Clin Pract 2020;26(2):431-38. [PMID: 31989727]
Stone EM, Kennedy-Hendricks A, Barry CL, et al. The role of stigma in U.S. primary care physicians’ treatment of opioid use disorder. Drug Alcohol Depend 2021;221:108627. [PMID: 33621805]
Tsai AC, Kiang MV, Barnett ML, et al. Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLoS Med 2019;16(11):e1002969. [PMID: 31770387]
Turan B, Budhwani H, Fazeli PL, et al. How does stigma affect people living with HIV? The mediating roles of internalized and anticipated HIV stigma in the effects of perceived community stigma on health and psychosocial outcomes. AIDS Behav 2017;21(1):283-91. [PMID: 27272742]
van Boekel LC, Brouwers EP, van Weeghel J, et al. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend 2013;131(1-2):23-35. [PMID: 23490450]
Adams K. K., Machnicz M., Sobieraj D. M. Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: a systematic review. Addict Sci Clin Pract 2021;16(1):36. [PMID: 34103087]
Ahmed S., Bhivandkar S., Lonergan B. B., et al. Microinduction of buprenorphine/naloxone: a review of the literature. Am J Addict 2021;30(4):305-15. [PMID: 33378137]
Ajazi E. M., Dasgupta N., Marshall S. W., et al. Revisiting the X:BOT naltrexone clinical trial using a comprehensive survival analysis. J Addict Med 2022;16(4):440-46. [PMID: 35960214]
Alexander R. S., Canver B. R., Sue K. L., et al. Xylazine and overdoses: trends, concerns, and recommendations. Am J Public Health 2022;112(8):1212-16. [PMID: 35830662]
Alford D. P., LaBelle C. T., Kretsch N., et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med 2011;171(5):425-31. [PMID: 21403039]
Altice F. L., Bruce R. D., Lucas G. M., et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr 2011;56(Suppl 1):S22-32. [PMID: 21317590]
Amato L., Davoli M., Perucci C. A., et al. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005;28(4):321-29. [PMID: 15925266]
Amato(a) L., Minozzi S., Davoli M., et al. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 2011;(9):CD005031. [PMID: 21901695]
Amato(b) L., Minozzi S., Davoli M., et al. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 2011;(10):CD004147. [PMID: 21975742]
Amram O., Amiri S., Panwala V., et al. The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era. Am J Drug Alcohol Abuse 2021;47(6):722-29. [PMID: 34670453]
APA. Diagnostic and statistical manual of mental disorders (DSM-5-TR): opioid use disorder; 2022. https://www.psychiatry.org/psychiatrists/practice/dsm
ASAM. The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. J Addict Med 2020;14(2S Suppl 1):1-91. [PMID: 32511106]
Belcher A. M., Coble K., Cole T. O., et al. Buprenorphine induction in a rural Maryland detention center during COVID-19: implementation and preliminary outcomes of a novel telemedicine treatment program for incarcerated individuals with opioid use disorder. Front Psychiatry 2021;12:703685. [PMID: 34777036]
Bergen A. W., Baurley J. W., Ervin C. M., et al. Effects of buprenorphine dose and therapeutic engagement on illicit opiate use in opioid use disorder treatment trials. Int J Environ Res Public Health 2022;19(7):4106. [PMID: 35409790]
Binswanger I. A., Blatchford P. J., Mueller S. R., et al. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med 2013;159(9):592-600. [PMID: 24189594]
Bisaga A., Mannelli P., Sullivan M. A., et al. Antagonists in the medical management of opioid use disorders: historical and existing treatment strategies. Am J Addict 2018;27(3):177-87. [PMID: 29596725]
Bozinoff N., Anderson B. J., Bailey G. L., et al. Correlates of stigma severity among persons seeking opioid detoxification. J Addict Med 2018;12(1):19-23. [PMID: 28885299]
Bozinoff N., Men S., Kurdyak P., et al. Prescribing characteristics associated with opioid overdose following buprenorphine taper. JAMA Netw Open 2022;5(9):e2234168. [PMID: 36173629]
Brooklyn J. R., Sigmon S. C. Vermont hub-and-spoke model of care for opioid use disorder: development, implementation, and impact. J Addict Med 2017;11(4):286-92. [PMID: 28379862]
Bruneau J., Ahamad K., Goyer MÈ, et al. Management of opioid use disorders: a national clinical practice guideline. CMAJ 2018;190(9):e247-57. [PMID: 29507156]
Busch S. H., Fiellin D. A., Chawarski M. C., et al. Cost-effectiveness of emergency department-initiated treatment for opioid dependence. Addiction 2017;112(11):2002-10. [PMID: 28815789]
Carroll J. J., Rich J. D., Green T. C. The more things change: buprenorphine/naloxone diversion continues while treatment remains inaccessible. J Addict Med 2018;12(6):459-65. [PMID: 30095563]
CDC. Linking people with opioid use disorder to medication treatment: a technical package of policy, programs, and practices. 2022 Mar 15. https://www.cdc.gov/drugoverdose/pdf/pubs/linkage-to-care_edited-pdf_508-3-15-2022.pdf [accessed 2022 Sep 8]
CDC(a). National Center for Health Statistics: Drug overdose deaths in the United States, 1999–2020. 2021 Dec 30. https://www.cdc.gov/nchs/products/databriefs/db428.htm [accessed 2022 Sep 8]
CDC(b). National Center for Health Statistics: Drug overdose deaths in the U.S. top 100,000 annually. 2021 Nov 17. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2021/20211117.htm [accessed 2022 Sep 29]
Chan B., Bougatsos C., Priest K. C., et al. Opioid treatment programs, telemedicine and COVID-19: a scoping review. Subst Abus 2022;43(1):539-46. [PMID: 34520702]
Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry 2021;34(4):344-50. [PMID: 33965972]
Cohen S. M., Weimer M. B., Levander X. A., et al. Low dose initiation of buprenorphine: a narrative review and practical approach. J Addict Med 2022;16(4):399-406. [PMID: 34954746]
Comer S. D., Sullivan M. A., Yu E., et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006;63(2):210-18. [PMID: 16461865]
Compton W. M., Volkow N. D. Extended-release buprenorphine and its evaluation with patient-reported outcomes. JAMA Netw Open 2021;4(5):e219708. [PMID: 33970262]
Cunningham C., Giovanniello A., Li X., et al. A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions. J Subst Abuse Treat 2011;40(4):349-56. [PMID: 21310583]
Cunningham C., Giovanniello A., Sacajiu G., et al. Buprenorphine treatment in an urban community health center: what to expect. Fam Med 2008;40(7):500-506. [PMID: 18928077]
Cunningham C., Khalid L., Deng Y., et al. A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic. J Subst Abuse Treat 2022;135:108641. [PMID: 34863608]
Cunningham(a) C., Giovanniello A., Kunins H. V., et al. Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users. Am J Addict 2013;22(4):352-57. [PMID: 23795874]
Cunningham(b) C. O., Roose R. J., Starrels J. L., et al. Prior buprenorphine experience is associated with office-based buprenorphine treatment outcomes. J Addict Med 2013;7(4):287-93. [PMID: 23722632]
D'Onofrio G., Chawarski M. C., O'Connor P. G., et al. Emergency department-initiated buprenorphine for opioid dependence with continuation in primary care: outcomes during and after intervention. J Gen Intern Med 2017;32(6):660-66. [PMID: 28194688]
D'Onofrio G., Hawk K. F., Perrone J., et al. Incidence of precipitated withdrawal during a multisite emergency department-initiated buprenorphine clinical trial in the era of fentanyl. JAMA Netw Open 2023;6(3):e236108. [PMID: 36995717]
D'Onofrio G., O'Connor P. G., Pantalon M. V., et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA 2015;313(16):1636-44. [PMID: 25919527]
Degenhardt L., Clark B., Macpherson G., et al. Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies. Lancet Psychiatry 2023;10(6):386-402. [PMID: 37167985]
Dhanda A., Salsitz E. A. The duration dilemma in opioid agonist therapy. J Opioid Manag 2021;17(4):353-58. [PMID: 34533830]
Dole V. P., Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride. JAMA 1965;193:646-50. [PMID: 14321530]
Dowell D., Ragan K. R., Jones C. M., et al. CDC clinical practice guideline for prescribing opioids for pain - United States, 2022. MMWR Recomm Rep 2022;71(3):1-95. [PMID: 36327391]
Englander H., Dobbertin K., Lind B. K., et al. Inpatient addiction medicine consultation and post-hospital substance use disorder treatment engagement: a propensity-matched analysis. J Gen Intern Med 2019;34(12):2796-2803. [PMID: 31410816]
Fareed A., Vayalapalli S., Casarella J., et al. Effect of buprenorphine dose on treatment outcome. J Addict Dis 2012;31(1):8-18. [PMID: 22356665]
FDA. Suboxone (buprenorphine and naloxone) sublingual film. 2010 Aug. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022410s000lbl.pdf [accessed 2019 Mar 20]
FDA. Revia (naltrexone hydrochloride tablets USP). 2013 Oct. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018932s017lbl.pdf [accessed 2022 Aug 3]
FDA. Methadone hydrochloride oral solution. 2014 Apr. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/090707orig1s003lbl.pdf [accessed 2019 Mar 20]
FDA. Sublocade (buprenorphine extended‐release) injection. 2017 Nov. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209819s000lbl.pdf [accessed 2023 Mar 14]
FDA. FDA issues warning letter for not including the most serious risks in advertisement for medication-assisted treatment drug. 2019 Dec 11. https://www.fda.gov/news-events/press-announcements/fda-issues-warning-letter-not-including-most-serious-risks-advertisement-medication-assisted [accessed 2022 Sep 8]
FDA. Vivitrol (naltrexone for extended-release injectable suspension). 2022 Sep. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021897s057lbl.pdf [accessed 2023 July 25]
Fiellin D. A., Barry D. T., Sullivan L. E., et al. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med 2013;126(1):74.e11-17. [PMID: 23260506]
Fiellin D. A., Schottenfeld R. S., Cutter C. J., et al. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med 2014;174(12):1947-54. [PMID: 25330017]
Fiellin D. A., Weiss L., Botsko M., et al. Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr 2011;56(Suppl 1):S33-38. [PMID: 21317592]
Gastfriend D. R. Intramuscular extended-release naltrexone: current evidence. Ann N Y Acad Sci 2011;1216:144-66. [PMID: 21272018]
Giacomuzzi S. M., Riemer Y., Ertl M., et al. Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment. Addiction 2003;98(5):693-702. [PMID: 12751987]
Grande L. A., Cundiff D., Greenwald M. K., et al. Evidence on buprenorphine dose limits: a review. J Addict Med 2023. [PMID: 37327067]
Greenwald M. K., Herring A. A., Perrone J., et al. A neuropharmacological model to explain buprenorphine induction challenges. Ann Emerg Med 2022;80(6):509-24. [PMID: 35940992]
Gruber V. A., Delucchi K. L., Kielstein A., et al. A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification. Drug Alcohol Depend 2008;94(1-3):199-206. [PMID: 18243585]
Gunderson E. W., Wang X. Q., Fiellin D. A., et al. Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial. Addict Behav 2010;35(5):537-40. [PMID: 20106601]
Gupta R., Holtgrave D. R., Ashburn M. A. Xylazine - medical and public health imperatives. N Engl J Med 2023;388(24):2209-12. [PMID: 37099338]
Haight B. R., Learned S. M., Laffont C. M., et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2019;393(10173):778-90. [PMID: 30792007]
Hämmig R., Kemter A., Strasser J., et al. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. Subst Abuse Rehabil 2016;7:99-105. [PMID: 27499655]
Handelsman L., Cochrane K. J., Aronson M. J., et al. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 1987;13(3):293-308. [PMID: 3687892]
Herring A. A., Perrone J., Nelson L. S. Managing opioid withdrawal in the emergency department with buprenorphine. Ann Emerg Med 2019;73(5):481-87. [PMID: 30616926]
Hoffman K. A., Foot C., Levander X. A., et al. Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: a mixed methods analysis. J Subst Abuse Treat 2022;141:108801. [PMID: 35589443]
Huhn A. S., Hobelmann J. G., Oyler G. A., et al. Protracted renal clearance of fentanyl in persons with opioid use disorder. Drug Alcohol Depend 2020;214:108147. [PMID: 32650192]
Humphreys K., Wing S., McCarty D., et al. Self-help organizations for alcohol and drug problems: toward evidence-based practice and policy. J Subst Abuse Treat 2004;26(3):151-58; discussion 159-65. [PMID: 15063905]
Institute of Medicine. Federal regulation of methadone treatment; 1995. https://www.ncbi.nlm.nih.gov/books/NBK232105/
Jaffe J. H., Zaks M. S., Washington E. N. Experience with the use of methadone in a multi-modality program for the treatment of narcotics users. Int J Addict 1969;4(3):481-90. https://doi.org/10.3109/10826086909062029
Jarvis B. P., Holtyn A. F., Berry M. S., et al. Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults. J Subst Abuse Treat 2018;85:38-44. [PMID: 28449955]
Jasinski D. R., Pevnick J. S., Griffith J. D. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978;35(4):501-16. [PMID: 215096]
Jones C. M., Shoff C., Hodges K., et al. Receipt of telehealth services, receipt and retention of medications for opioid use disorder, and medically treated overdose among medicare beneficiaries before and during the COVID-19 pandemic. JAMA Psychiatry 2022;79(10):981-92. [PMID: 36044198]
Jones(a) C. M., Shoff C., Blanco C., et al. Association of receipt of opioid use disorder-related telehealth services and medications for opioid use disorder with fatal drug overdoses among Medicare beneficiaries before and during the COVID-19 pandemic. JAMA Psychiatry 2023;80(5):508-14. [PMID: 36988913]
Jones(b) C. M., Han B., Baldwin G. T., et al. Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021. JAMA Network Open 2023;6(8):e2327488. https://doi.org/10.1001/jamanetworkopen.2023.27488
Kampman K., Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med 2015;9(5):358-67. [PMID: 26406300]
Korn W. R., Stone M. D., Haviland K. L., et al. High prevalence of xylazine among fentanyl screen-positive urines from hospitalized patients, Philadelphia, 2021. Clin Chim Acta 2021;521:151-54. [PMID: 34265257]
Krawczyk N., Rivera B. D., Jent V., et al. Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019. Int J Drug Policy 2022;110:103786. [PMID: 35934583]
Larochelle M. R., Bernson D., Land T., et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med 2018;169(3):137-45. [PMID: 29913516]
Lee J. D., Grossman E., DiRocco D., et al. Home buprenorphine/naloxone induction in primary care. J Gen Intern Med 2009;24(2):226-32. [PMID: 19089508]
Lee J. D., Malone M., McDonald R., et al. Comparison of treatment retention of adults with opioid addiction managed with extended-release buprenorphine vs daily sublingual buprenorphine-naloxone at time of release from jail. JAMA Netw Open 2021;4(9):e2123032. [PMID: 34495340]
Lee J. D., Nunes E. V., Novo P., et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet 2018;391(10118):309-18. [PMID: 29150198]
Liebschutz J. M., Crooks D., Herman D., et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med 2014;174(8):1369-76. [PMID: 25090173]
Lind B., Chen S., Weatherburn D., et al. Effectiveness of methadone maintenance treatment in controlling crime: an Australian aggregate-level analysis. Br J Criminol 2005;45(2):201-11. https://www.ojp.gov/ncjrs/virtual-library/abstracts/effectiveness-methadone-maintenance-treatment-controlling-crime
Ling W., Wesson D. R. Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug Alcohol Depend 2003;70(2 Suppl):S49-57. [PMID: 12738350]
Lofwall M. R., Walsh S. L., Nunes E. V., et al. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial. JAMA Intern Med 2018;178(6):764-73. [PMID: 29799968]
Lucas G. M., Chaudhry A., Hsu J., et al. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: a randomized trial. Ann Intern Med 2010;152(11):704-11. [PMID: 20513828]
Ma J., Bao Y. P., Wang R. J., et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry 2019;24(12):1868-83. [PMID: 29934549]
Magura S., Lee S. J., Salsitz E. A., et al. Outcomes of buprenorphine maintenance in office-based practice. J Addict Dis 2007;26(2):13-23. [PMID: 17594994]
Maldonado R. [The endogenous opioid system and drug addiction]. Ann Pharm Fr 2010;68(1):3-11. [PMID: 20176158]
Mattick R. P., Ali R., White J. M., et al. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003;98(4):441-52. [PMID: 12653814]
Mattick R. P., Breen C., Kimber J., et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009;(3):CD002209. [PMID: 19588333]
Mattick R. P., Breen C., Kimber J., et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014;(2):CD002207. [PMID: 24500948]
McLellan A. T., Starrels J. L., Tai B., et al. Can substance use disorders be managed using the chronic care model? Review and recommendations from a NIDA consensus group. Public Health Rev 2014;35(2). [PMID: 26568649]
Mello N. K., Mendelson J. H. Buprenorphine suppresses heroin use by heroin addicts. Science 1980;207(4431):657-59. [PMID: 7352279]
Minozzi S., Amato L., Vecchi S., et al. Maintenance agonist treatments for opiate dependent pregnant women. Cochrane Database Syst Rev 2008;(2):CD006318. [PMID: 18425946]
Minozzi S., Amato L., Vecchi S., et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2011;(4):CD001333. [PMID: 21491383]
Mintzer I. L., Eisenberg M., Terra M., et al. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med 2007;5(2):146-50. [PMID: 17389539]
Monico L. B., Mitchell S. G., Gryczynski J., et al. Prior experience with non-prescribed buprenorphine: role in treatment entry and retention. J Subst Abuse Treat 2015;57:57-62. [PMID: 25980599]
Morgan J. R., Schackman B. R., Leff J. A., et al. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat 2018;85:90-96. [PMID: 28733097]
Morgan J. R., Schackman B. R., Weinstein Z. M., et al. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. Drug Alcohol Depend 2019;200:34-39. [PMID: 31082666]
NEJM Catalyst. Addressing equity in telemedicine for chronic disease management during the COVID-19 pandemic. 2020 May 4. https://catalyst.nejm.org/doi/full/10.1056/CAT.20.0123 [accessed 2022 Sep 8]
Norton B. L., Beitin A., Glenn M., et al. Retention in buprenorphine treatment is associated with improved HCV care outcomes. J Subst Abuse Treat 2017;75:38-42. [PMID: 28237052]
NYSDOH. New York State Medicaid update: comprehensive guidance regarding use of telehealth including telephonic services. 2021 Jul. https://www.health.ny.gov/health_care/medicaid/program/update/2021/no07_2021-06_covid-19_telehealth.htm#telephonic [accessed 2022 Sep 8]
Olfson M., Wall M., Wang S., et al. Risks of fatal opioid overdose during the first year following nonfatal overdose. Drug Alcohol Depend 2018;190:112-19. [PMID: 30005310]
Payne B. E., Klein J. W., Simon C. B., et al. Effect of lowering initiation thresholds in a primary care-based buprenorphine treatment program. Drug Alcohol Depend 2019;200:71-77. [PMID: 31103879]
Peckham A. M., Kehoe L. G., Gray J. R., et al. Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: a retrospective case series. J Subst Abuse Treat 2021;126:108316. [PMID: 34116808]
Peterkin A., Laks J., Weinstein Z. M. Current best practices for acute and chronic management of patients with opioid use disorder. Med Clin North Am 2022;106(1):61-80. [PMID: 34823735]
Radosh L., Gosala S., Santoro W. Extended-release buprenorphine: sharing clinical pearls, protocols and possibilities from 3000 injections. 53rd Annual Conference of the American Society of Addiction Medicine; 2022 Apr 2. https://c53ac34983397363b9e2-fa85729df59db74d0fed9dc21ffea231.ssl.cf1.rackcdn.com/1908000-1187297-002.pdf
Rudd R. A., Seth P., David F., et al. Increases in drug and opioid-involved overdose deaths - United States, 2010-2015. MMWR Morb Mortal Wkly Rep 2016;65(50-51):1445-52. [PMID: 28033313]
Ruetsch C., Tkacz J., McPherson T. L., et al. The effect of telephonic patient support on treatment for opioid dependence: outcomes at one year follow-up. Addict Behav 2012;37(5):686-89. [PMID: 22348921]
Samet J. H., Friedmann P., Saitz R. Benefits of linking primary medical care and substance abuse services: patient, provider, and societal perspectives. Arch Intern Med 2001;161(1):85-91. [PMID: 11146702]
SAMHSA. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. 2004. https://www.ncbi.nlm.nih.gov/books/NBK64245/ [accessed September 6, 2023]
SAMHSA. Substance abuse treatment advisory: protracted withdrawal. 2010 Jul. https://store.samhsa.gov/sites/default/files/d7/priv/sma10-4554.pdf [accessed 2023 Feb 15]
SAMHSA. FAQs: provision of methadone and buprenorphine for the treatment of opioid use disorder in the COVID-19 emergency. 2020 Apr 21. https://www.samhsa.gov/sites/default/files/faqs-for-oud-prescribing-and-dispensing.pdf [accessed 2022 Sep 8]
SAMHSA. Methadone take-home flexibilities extension guidance. 2023 Aug 4. https://www.samhsa.gov/medications-substance-use-disorders/statutes-regulations-guidelines/methadone-guidance [accessed 2023 Apr 21]
SAMHSA(a). 2018 National Survey of Drug Use and Health (NSDUH) releases. 2019 Aug 20. https://www.samhsa.gov/data/release/2018-national-survey-drug-use-and-health-nsduh-releases [accessed 2018 Aug 21]
SAMHSA(a). 2020 NSDUH Annual National Report. 2021 Oct 25. https://www.samhsa.gov/data/report/2020-nsduh-annual-national-report [accessed 2022 Sep 8]
SAMHSA(b). The National Survey on Drug Use and Health: 2018. 2019 Aug 20. https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/Assistant-Secretary-nsduh2018_presentation.pdf [accessed 2019 Aug 21]
SAMHSA(b). Medications for opioid use disorder: TIP 63. 2021 Nov 10. https://store.samhsa.gov/sites/default/files/pep21-02-01-002.pdf [accessed 2023 Feb 15]
Saxon A. J., Akerman S. C., Liu C. C., et al. Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry. Addiction 2018;113(8):1477-87. [PMID: 29493836]
Scholl L., Seth P., Kariisa M., et al. Drug and opioid-involved overdose deaths - United States, 2013-2017. MMWR Morb Mortal Wkly Rep 2018;67(5152):1419-27. [PMID: 30605448]
Schuckit M. A. Treatment of opioid-use disorders. N Engl J Med 2016;375(4):357-68. [PMID: 27464203]
Sigmon S. C., Dunn K. E., Saulsgiver K., et al. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. JAMA Psychiatry 2013;70(12):1347-54. [PMID: 24153411]
Silverstein S. M., Daniulaityte R., Martins S. S., et al. "Everything is not right anymore": buprenorphine experiences in an era of illicit fentanyl. Int J Drug Policy 2019;74:76-83. [PMID: 31563098]
Snyder H., Chau B., Kalmin M. M., et al. High-dose buprenorphine initiation in the emergency department among patients using fentanyl and other opioids. JAMA Netw Open 2023;6(3):e231572. [PMID: 36867410]
Sohler N. L., Li X., Kunins H. V., et al. Home- versus office-based buprenorphine inductions for opioid-dependent patients. J Subst Abuse Treat 2010;38(2):153-59. [PMID: 19801178]
Sordo L., Barrio G., Bravo M. J., et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 2017;357:j1550. [PMID: 28446428]
Soyka M., Träder A., Klotsche J., et al. Six-year mortality rates of patients in methadone and buprenorphine maintenance therapy: results from a nationally representative cohort study. J Clin Psychopharmacol 2011;31(5):678-80. [PMID: 21881461]
Stone A. C., Carroll J. J., Rich J. D., et al. One year of methadone maintenance treatment in a fentanyl endemic area: safety, repeated exposure, retention, and remission. J Subst Abuse Treat 2020;115:108031. [PMID: 32600619]
Sue K. L., Cohen S., Tilley J., et al. A plea from people who use drugs to clinicians: new ways to initiate buprenorphine are urgently needed in the fentanyl era. J Addict Med 2022;16(4):389-91. [PMID: 35020693]
Sullivan L. E., Botsko M., Cunningham C. O., et al. The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr 2011;56(Suppl 1):S54-61. [PMID: 21317595]
Tanum L., Solli K. K., Latif Z. E., et al. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiatry 2017;74(12):1197-1205. [PMID: 29049469]
Tetrault J. M., Moore B. A., Barry D. T., et al. Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients. J Subst Abuse Treat 2012;43(4):433-39. [PMID: 22938914]
Tiihonen J., Krupitsky E., Verbitskaya E., et al. Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial. Am J Psychiatry 2012;169(5):531-36. [PMID: 22764364]
Tofighi B., McNeely J., Walzer D., et al. A telemedicine buprenorphine clinic to serve New York City: initial evaluation of the NYC public hospital system's initiative to expand treatment access during the COVID-19 pandemic. J Addict Med 2022;16(1):e40-43. [PMID: 33560696]
Torres-Lockhart K. E., Lu T. Y., Weimer M. B., et al. Clinical management of opioid withdrawal. Addiction 2022;117(9):2540-50. [PMID: 35112746]
Varshneya N. B., Thakrar A. P., Hobelmann J. G., et al. Evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl. J Addict Med 2022;16(4):e265-68. [PMID: 34816821]
Volkow N. D., Jones E. B., Einstein E. B., et al. Prevention and treatment of opioid misuse and addiction: a review. JAMA Psychiatry 2019;76(2):208-16. [PMID: 30516809]
Volkow N. D., Koob G. Brain disease model of addiction: why is it so controversial?. Lancet Psychiatry 2015;2(8):677-79. [PMID: 26249284]
Volkow N. D., Koob G. F., McLellan A. T. Neurobiologic advances from the brain disease model of addiction. N Engl J Med 2016;374(4):363-71. [PMID: 26816013]
Wakeman S. E., Kane M., Powell E., et al. A hospital-wide initiative to redesign substance use disorder care: impact on pharmacotherapy initiation. Subst Abus 2021;42(4):767-74. [PMID: 33270549]
Wakeman S. E., Larochelle M. R., Ameli O., et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open 2020;3(2):e1920622. [PMID: 32022884]
Weimer M. B., Herring A. A., Kawasaki S. S., et al. ASAM clinical considerations: buprenorphine treatment of opioid use disorder for individuals using high-potency synthetic opioids. J Addict Med 2023. [PMID: 37505909]
Weintraub E., Seneviratne C., Anane J., et al. Mobile telemedicine for buprenorphine treatment in rural populations with opioid use disorder. JAMA Netw Open 2021;4(8):e2118487. [PMID: 34448869]
Weiss R. D., Potter J. S., Fiellin D. A., et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry 2011;68(12):1238-46. [PMID: 22065255]
Wesson D. R., Ling W. The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs 2003;35(2):253-59. [PMID: 12924748]
Whitley S. D., Sohler N. L., Kunins H. V., et al. Factors associated with complicated buprenorphine inductions. J Subst Abuse Treat 2010;39(1):51-57. [PMID: 20682186]
Williams J. T., Ingram S. L., Henderson G., et al. Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev 2013;65(1):223-54. [PMID: 23321159]
Williams A. R., Aronowitz S., Gallagher R., et al. A virtual-first telehealth treatment model for opioid use disorder. J Gen Intern Med 2023;38(3):814-16. [PMID: 36456841]
Williams A. R., Mauro C. M., Feng T., et al. Non-prescribed buprenorphine preceding treatment intake and clinical outcomes for opioid use disorder. J Subst Abuse Treat 2022;139:108770. [PMID: 35337715]
Woody G. E., Poole S. A., Subramaniam G., et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA 2008;300(17):2003-11. [PMID: 18984887]
Yarborough B. J., Stumbo S. P., McCarty D., et al. Methadone, buprenorphine and preferences for opioid agonist treatment: a qualitative analysis. Drug Alcohol Depend 2016;160:112-18. [PMID: 26796596]
Updates, Authorship, and Related Guidelines
|Updates, Authorship, and Related Guidelines|
|Date of original publication||August 29, 2019|
|Date of current publication||September 12, 2023|
|Highlights of changes, additions, and updates in the September 12, 2023 edition||
|Intended users||Primary care and other clinicians in New York State who provide outpatient medical care for adults with opioid use disorder|
Tiffany Lu, MD, MS
Susan D. Whitley, MD; Timothy J. Wiegand, MD; Sharon L. Stancliff, MD; Christopher J. Hoffmann, MD, MPH; Charles J. Gonzalez, MD
|Author and writing group conflict of interest disclosures||There are no author or writing group conflict of interest disclosures|
|Developer and funder|
See Guideline Development and Recommendation Ratings Scheme, below.
|Related NYSDOH AI guidelines|
Guideline Development and Recommendation Ratings
|Guideline Development: New York State Department of Health AIDS Institute Clinical Guidelines Program|
|Program manager||Clinical Guidelines Program, Johns Hopkins University School of Medicine, Division of Infectious Diseases. See Program Leadership and Staff.|
|Mission||To produce and disseminate evidence-based, state-of-the-art clinical practice guidelines that establish uniform standards of care for practitioners who provide prevention or treatment of HIV, viral hepatitis, other sexually transmitted infections, and substance use disorders for adults throughout New York State in the wide array of settings in which those services are delivered.|
|Expert committees||The NYSDOH AI Medical Director invites and appoints committees of clinical and public health experts from throughout New York State to ensure that the guidelines are practical, immediately applicable, and meet the needs of care providers and stakeholders in all major regions of New York State, all relevant clinical practice settings, key New York State agencies, and community service organizations.|
|Disclosure and management of conflicts of interest||
|Evidence collection and review||
|Review and approval process||
|Recommendation Ratings Scheme|
|Strength||Quality of Evidence|
|A||Strong||1||Based on published results of at least 1 randomized clinical trial with clinical outcomes or validated laboratory endpoints.|
|B||Moderate||*||Based on either a self-evident conclusion; conclusive, published, in vitro data; or well-established practice that cannot be tested because ethics would preclude a clinical trial.|
|C||Optional||2||Based on published results of at least 1 well-designed, nonrandomized clinical trial or observational cohort study with long-term clinical outcomes.|
|2†||Extrapolated from published results of well-designed studies (including nonrandomized clinical trials) conducted in populations other than those specifically addressed by a recommendation. The source(s) of the extrapolated evidence and the rationale for the extrapolation are provided in the guideline text. One example would be results of studies conducted predominantly in a subpopulation (e.g., one gender) that the committee determines to be generalizable to the population under consideration in the guideline.|
|3||Based on committee expert opinion, with rationale provided in the guideline text.|
Last updated on November 10, 2023